Oxford Biomedica
OrganizationHeard in 3 episodes across 2 shows since Aug 2026
Oxford Biomedica (OXB) is a leading gene and cell therapy company specializing in the development and manufacturing of gene-based medicines. Operating as a contract development and manufacturing organization (CDMO), it provides critical viral vector solutions to power progressive cell and gene therapies globally.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 3 |
| Sep 2026 | 0 |
| Oct 2026 | 0 |
| Nov 2026 | 0 |
Email alert
Email me when Oxford Biomedica comes up on a podcast
One email a week at most, with the new episodes that mention Oxford Biomedica. Free, no account needed, unsubscribe in one click.
What experts have said about Oxford Biomedica
6 statements · 6 negative
Oxford Biomedica cut its full-year revenue and profitability guidance.
“they cut their full year revenue and profitability guidance.”
Open the episode · Frasers Group Up, Royal Unibrew Drops, OXB DownListen at 4:05
Oxford Biomedica remains loss-making and cash-burning, making valuation difficult.
“it doesn't make any money. It's loss-making and cash-burning, so it's quite a leap of faith here to actually value it.”
Open the episode · Paul's Podcast - Fri 7 Aug 2026Listen at 14:58
Oxford Biomedica is loss-making and consuming cash, complicating valuation.
“It's loss-making and cash-burning, so it's quite a leap of faith here to actually value it.”
Open the episode · Paul's Podcast - Fri 7 Aug 2026Listen at 14:59
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
3 episodes featuring Oxford Biomedica, newest first
- Aug 18, 2026
European stocks split on weak results and shifting expectationsStock MoversAug 18, 2026 - Aug 18, 2026
Frasers Group nears control of Hugo Boss as rivals stumbleStock MoversAug 18, 2026 - Aug 7, 2026
Paul Scott opens a delayed small-cap market discussionUK Small/Mid Caps with Paul ScottAug 7, 2026